NivolumabCytokine-release-syndrome and derangement of renal function secondary to tumour-lysis-syndrome: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1687卷 / 1期

关键词：

D O I：

10.1007/s40278-018-41593-7

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：172 / 172

相关论文

共 50 条

[31] BromopyruvateFirst report of tumour lysis syndrome: case report
Reactions Weekly, 2012, 1405 (1) : 11 - 11
[32] ThalidomideFirst report of tumour lysis syndrome: case report
Reactions Weekly, 2002, 908 (1) : 10 - 11
[33] EribulinFirst report of tumour lysis syndrome: case report
Reactions Weekly, 2019, 1743 (1) : 86 - 86
[34] Ipilimumab/nivolumabCytokine releasing syndrome: case report
Reactions Weekly, 2025, 2052 (1) : 224 - 224
[35] Carboplatin/etoposideAcute tumour lysis syndrome: case report
Reactions Weekly, 2025, 2056 (1) : 124 - 124
[36] Ibrutinib/VenetoclaxHyperkalaemia and tumour lysis syndrome: case report
Reactions Weekly, 2024, 2024 (1) : 227 - 227
[37] Antineoplastics/romidepsinNeutropenia and tumour lysis syndrome: case report
Reactions Weekly, 2018, 1693 (1) : 53 - 53
[38] DexamethasoneRenal failure and tumour lysis syndrome: case report
Reactions Weekly, 2021, 1853 (1) : 168 - 168
[39] CetuximabFatal tumour lysis syndrome (first report): case report
Reactions Weekly, 2008, 1203 (1) : 15 - 15
[40] CapecitabineFirst report of fatal tumour lysis syndrome: case report
Reactions Weekly, 2004, 1006 (1) : 8 - 8

← 1 2 3 4 5 →